Shares of AEVEX Corp. shifted sharply higher on Monday, up 7.1% to $14.27, after a punishing five-session slide that dragged the stock to a 52-week low of $13.07 — a gut-check moment for a company that priced its IPO at $20 barely three months ago. The bounce looks like bargain-hunting after severe dilution anxiety, but the stock remains deeply underwater, and the path back will demand more than a single green day.
Two Share Sales in Three Months Flooded the Market With Stock. AEVEX's April IPO generated roughly $320 million in gross proceeds from 16 million shares at $20 apiece. Just six weeks later, the company completed a second offering of 5.7 million newly issued shares plus 2.3 million shares sold by existing stockholders at $27.00 per share. That means roughly 24 million new or secondary shares hit the market since mid-April. Madison Dearborn Partners' funds still hold about 70% of voting power , so more selling by insiders remains a live risk. At today's price, AEVEX sits 29% below its $20 IPO price and 47% below the $27 secondary-offering level — a stark signal that supply overwhelmed demand.
The Business Is Growing Fast, But Debt and Cash Burn Complicate the Picture. Q1 2026 saw revenue surge 307% year-over-year to $216.7 million.
Guidance for 2026 projects $600–$620 million in revenue. Yet operating cash flow was a negative $10.4 million as working capital expanded to support growth , and total debt sits at $265.6 million against just $27.5 million in cash.
Interest payments are not well covered by earnings, so additional equity capital may be viewed as necessary support rather than optional funding.
Pentagon Contracts Keep Coming — But Haven't Stopped the Bleeding. Recent wins include a $50 million Air Force contract for unmanned mission support and a $17.5 million follow-on under its Global Solutions portfolio.
Funded backlog was $356.6 million, heavily concentrated in U.S. Government work. Those orders underwrite near-term revenue but haven't calmed investors spooked by dilution and insider exits.
Wall Street Still Sees Massive Upside — If Execution Holds. Nine analysts rate AVEX a "Strong Buy" with an average 12-month target of $35.75 — roughly 150% above today's price. That gap reflects either deep value or misplaced optimism; the answer depends on whether AEVEX can convert contract wins into free cash flow before it needs another capital raise.